

Jennifer T Loud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3377020/publications.pdf>

Version: 2024-02-01

40
papers

2,375
citations

331538

21
h-index

289141

40
g-index

41
all docs

41
docs citations

41
times ranked

4755
citing authors

#	ARTICLE	IF	CITATIONS
1	Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 159-167.	1.1	5
2	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
3	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16
4	Identification of 22 susceptibility loci associated with testicular germ cell tumors. <i>Nature Communications</i> , 2021, 12, 4487.	5.8	27
5	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
6	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
7	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
8	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
9	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	3.4	48
10	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	0.6	32
11	Couples coping with screening burden and diagnostic uncertainty in Li-Fraumeni syndrome: Connection versus independence. <i>Journal of Psychosocial Oncology</i> , 2019, 37, 178-193.	0.6	21
12	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. <i>JAMA Oncology</i> , 2019, 5, 514.	3.4	43
13	Reproductive factors associated with breast cancer risk in Li-Fraumeni syndrome. <i>European Journal of Cancer</i> , 2019, 116, 199-206.	1.3	10
14	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19
15	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90
16	Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 719-726.	1.1	5
17	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
18	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224

#	ARTICLE	IF	CITATIONS
19	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. <i>Genome Medicine</i> , 2018, 10, 99.	3.6	15
20	Mosaic chromosome Y loss and testicular germ cell tumor risk. <i>Journal of Human Genetics</i> , 2017, 62, 637-640.	1.1	34
21	Introduction. <i>Seminars in Oncology Nursing</i> , 2017, 33, 119-120.	0.7	0
22	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
23	Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort. <i>JAMA Oncology</i> , 2017, 3, 1640.	3.4	43
24	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. <i>JAMA Oncology</i> , 2017, 3, 1634.	3.4	148
25	Research participant interest in primary, secondary, and incidental genomic findings. <i>Genetics in Medicine</i> , 2016, 18, 1218-1225.	1.1	24
26	Risks of first and subsequent cancers among <i>TP53</i> mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. <i>Cancer</i> , 2016, 122, 3673-3681.	2.0	346
27	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
28	Nontesticular cancers in relatives of testicular germ cell tumor (TGCT) patients from multiple TGCT families. <i>Cancer Medicine</i> , 2015, 4, 1069-1078.	1.3	2
29	Rare inactivating PDE11A variants associated with testicular germ cell tumors. <i>Endocrine-Related Cancer</i> , 2015, 22, 909-917.	1.6	24
30	Prospectively Identified Incident Testicular Cancer Risk in a Familial Testicular Cancer Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1614-1621.	1.1	4
31	Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 652-657.	3.2	138
32	Effects of false-positive cancer screenings and cancer worry on risk-reducing surgery among <i>BRCA1/2</i> carriers. <i>Health Psychology</i> , 2015, 34, 709-717.	1.3	19
33	Circulating estrogens and estrogens within the breast among postmenopausal <i>BRCA1/2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 691-692.	1.1	1
34	Circulating estrogens and estrogens within the breast among postmenopausal <i>BRCA1/2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 517-529.	1.1	13
35	Ductal Lavage in Women from <i>BRCA1/2</i> Families: Is There a Future for Ductal Lavage in Women at Increased Genetic Risk of Breast Cancer?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1243-1251.	1.1	25
36	Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer. <i>BMC Women's Health</i> , 2009, 9, 20.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Disclosure of positive BRCA1/2-mutation status in young couples: The journey from uncertainty to bonding through partner support.. Families, Systems and Health, 2008, 26, 296-316.	0.4	36
38	Deliberate Deceit of Family Members: A Challenge to Providers of Clinical Genetics Services. Journal of Clinical Oncology, 2006, 24, 1643-1646.	0.8	15
39	The art and science of cancer nursing in the genomic era. Seminars in Oncology Nursing, 2004, 20, 143-144.	0.7	2
40	Applications of Advances in Molecular Biology and Genomics to Clinical Cancer Care. Cancer Nursing, 2002, 25, 110-122.	0.7	5